Announcements Trials
Browse Landscape

Phase

Phase 3 21Phase NA 7Phase 2/3 6Phase 1 6Phase 2 5Phase 1/2 3Phase 4 2Phase EARLY_PHASE1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Conditions

Breast Neoplasms 24Neoplasms 11Carcinoma, Non-Small-Cell Lung 9Prostatic Neoplasms 8Multiple Myeloma 8Lung Neoplasms 6Melanoma 5Leukemia, Myeloid, Acute 5Neoplasm Metastasis 4Glioma 4Colorectal Neoplasms 4Carcinoma, Hepatocellular 4Tuberous Sclerosis 3Stomach Neoplasms 3Sarcoma 3Papillomavirus Infections 3Leiomyoma 3Hematologic Neoplasms 3Glioblastoma 3Carcinoma, Renal Cell 3Polycythemia Vera 2Pain 2Oligodendroglioma 2Neoplasms by Site 2Myasthenia Gravis 2Leukemia, Myelogenous, Chronic, BCR-ABL Positive 2Heart Failure 2Febrile Neutropenia 2Endometrial Neoplasms 2Bronchiolitis Obliterans Syndrome 2

Interventions

rozanolixizumab 1ravulizumab 1Prednisone 1Prednisolone 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 4 × Myasthenia Gravis × 90 days × Clear all
NCT07246564 2026-05-22

Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myasthenia Gravis

UCB Pharma

Phase 4 Recruiting
40 enrolled

Myasthenia Gravis

NCT07221838 2026-04-09

OCTAGON

Alexion Pharmaceuticals, Inc.

Phase 4 Recruiting
75 enrolled

Adrenal Insufficiency, Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡